Phase II PICCOLO Trial Results-Recording

Video Transcription

Video Summary

In a recent discussion, Wendell Nauman of Levine Cancer Atrium Health and Angeles Alvarez-Sicord of Duke University delved into the findings of the PICOLO trial presented at ESMO. The trial assessed the drug mirvetuximab soravtansine (MYR) in treating recurrent platinum-sensitive ovarian cancer with high folate receptor alpha expression.<br /><br />The results revealed a significant 51.9% objective response rate, even in heavily pretreated patients, including those previously exposed to PARP inhibitors. The median duration of response was 8.25 months overall, with no new safety concerns identified beyond manageable side effects like ocular toxicity. The trial's findings suggest MYR could be a promising option for patients unsuitable for further platinum treatments, potentially changing clinical practice landscapes with ongoing studies exploring its use in combination therapies and maintenance settings.

Keywords

PICOLO trial

mirvetuximab soravtansine

ovarian cancer

folate receptor alpha

objective response rate

clinical practice